Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Erratum to: Predictors of Perianal Fistula Relapse in Crohn's Disease.

Inflammatory bowel diseases

Malian A, Rivière P, Bouchard D, Pigot F, Eléouet-Kaplan M, Favreau-Weltzer C, Poullenot F, Laharie D.
PMID: 33277906
Inflamm Bowel Dis. 2021 Jul 27;27(8):1365. doi: 10.1093/ibd/izaa272.

No abstract available.

Cite
Malian A, Rivière P, Bouchard D, et al. Erratum to: Predictors of Perianal Fistula Relapse in Crohn's Disease. Inflamm Bowel Dis. 2021;27(8):1365doi: 10.1093/ibd/izaa272.
Malian, A., Rivière, P., Bouchard, D., Pigot, F., Eléouet-Kaplan, M., Favreau-Weltzer, C., Poullenot, F., & Laharie, D. (2021). Erratum to: Predictors of Perianal Fistula Relapse in Crohn's Disease. Inflammatory bowel diseases, 27(8), 1365. https://doi.org/10.1093/ibd/izaa272
Malian, Audrey, et al. "Erratum to: Predictors of Perianal Fistula Relapse in Crohn's Disease." Inflammatory bowel diseases vol. 27,8 (2021): 1365. doi: https://doi.org/10.1093/ibd/izaa272
Malian A, Rivière P, Bouchard D, Pigot F, Eléouet-Kaplan M, Favreau-Weltzer C, Poullenot F, Laharie D. Erratum to: Predictors of Perianal Fistula Relapse in Crohn's Disease. Inflamm Bowel Dis. 2021 Jul 27;27(8):1365. doi: 10.1093/ibd/izaa272. PMID: 33277906.
Copy Download .nbib Format: NLM
Malnutrition After Bariatric Surgery Requiring Artificial Nutrition Supplies.

Obesity surgery

Loddo C, Poullenot F, Rivière P, Pupier E, Monsaingeon-Henry M, Gronnier C, Collet D, Gatta-Cherifi B.
PMID: 29568984
Obes Surg. 2018 Jun;28(6):1803-1805. doi: 10.1007/s11695-018-3207-y.

No abstract available.

Cite
Loddo C, Poullenot F, Rivière P, et al. Malnutrition After Bariatric Surgery Requiring Artificial Nutrition Supplies. Obes Surg. 2018;28(6):1803-1805doi: 10.1007/s11695-018-3207-y.
Loddo, C., Poullenot, F., Rivière, P., Pupier, E., Monsaingeon-Henry, M., Gronnier, C., Collet, D., & Gatta-Cherifi, B. (2018). Malnutrition After Bariatric Surgery Requiring Artificial Nutrition Supplies. Obesity surgery, 28(6), 1803-1805. https://doi.org/10.1007/s11695-018-3207-y
Loddo, Céline, et al. "Malnutrition After Bariatric Surgery Requiring Artificial Nutrition Supplies." Obesity surgery vol. 28,6 (2018): 1803-1805. doi: https://doi.org/10.1007/s11695-018-3207-y
Loddo C, Poullenot F, Rivière P, Pupier E, Monsaingeon-Henry M, Gronnier C, Collet D, Gatta-Cherifi B. Malnutrition After Bariatric Surgery Requiring Artificial Nutrition Supplies. Obes Surg. 2018 Jun;28(6):1803-1805. doi: 10.1007/s11695-018-3207-y. PMID: 29568984.
Copy Download .nbib Format: NLM
Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy.

Immunotherapy

Domblides C, Gross-Goupil M, Ravaud A, Poullenot F, Daste A.
PMID: 33906378
Immunotherapy. 2021 Jun;13(9):741-744. doi: 10.2217/imt-2020-0282. Epub 2021 Apr 28.

Immune checkpoint inhibitors have been approved as adjuvant therapy. Adverse immune events occurred during the administration of treatment, and delayed immune-related events have low incidence. A 66-year-old man was treated for hypopharynx cancer in 2012. In 2019, he was...

Cite
Domblides C, Gross-Goupil M, Ravaud A, et al. Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy. Immunotherapy. 2021;13(9):741-744doi: 10.2217/imt-2020-0282.
Domblides, C., Gross-Goupil, M., Ravaud, A., Poullenot, F., & Daste, A. (2021). Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy. Immunotherapy, 13(9), 741-744. https://doi.org/10.2217/imt-2020-0282
Domblides, Charlotte, et al. "Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy." Immunotherapy vol. 13,9 (2021): 741-744. doi: https://doi.org/10.2217/imt-2020-0282
Domblides C, Gross-Goupil M, Ravaud A, Poullenot F, Daste A. Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy. Immunotherapy. 2021 Jun;13(9):741-744. doi: 10.2217/imt-2020-0282. Epub 2021 Apr 28. PMID: 33906378.
Copy Download .nbib Format: NLM
Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study.

Clinics and research in hepatology and gastroenterology

Tilmant M, Serrero M, Poullenot F, Bouguen G, Pariente B, Altwegg R, Basile P, Filippi J, Vanelslander P, Buisson A, Desjeux A, Laharie D, Le Balch E, Nachury M, Boivineau L, Savoye G, Hebuterne X, Poincloux L, Vuitton L, Brazier F, Yzet C, Lamrani A, Peyrin-Biroulet L, Fumery M.
PMID: 33214090
Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101561. doi: 10.1016/j.clinre.2020.10.006. Epub 2020 Nov 16.

INTRODUCTION: While endoscopic balloon dilation (EBD) is widely used to manage ileal strictures, EBD of colorectal strictures remains poorly investigated in Crohn's disease (CD).METHODS: We performed a retrospective study that included all consecutive CD patients who underwent EBD for...

Cite
Tilmant M, Serrero M, Poullenot F, et al. Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study. Clin Res Hepatol Gastroenterol. 2020;45(5):101561doi: 10.1016/j.clinre.2020.10.006.
Tilmant, M., Serrero, M., Poullenot, F., Bouguen, G., Pariente, B., Altwegg, R., Basile, P., Filippi, J., Vanelslander, P., Buisson, A., Desjeux, A., Laharie, D., Le Balch, E., Nachury, M., Boivineau, L., Savoye, G., Hebuterne, X., Poincloux, L., Vuitton, L., Brazier, F., Yzet, C., Lamrani, A., Peyrin-Biroulet, L., & Fumery, M. (2021). Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study. Clinics and research in hepatology and gastroenterology, 45(5), 101561. https://doi.org/10.1016/j.clinre.2020.10.006
Tilmant, Marion, et al. "Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study." Clinics and research in hepatology and gastroenterology vol. 45,5 (2021): 101561. doi: https://doi.org/10.1016/j.clinre.2020.10.006
Tilmant M, Serrero M, Poullenot F, Bouguen G, Pariente B, Altwegg R, Basile P, Filippi J, Vanelslander P, Buisson A, Desjeux A, Laharie D, Le Balch E, Nachury M, Boivineau L, Savoye G, Hebuterne X, Poincloux L, Vuitton L, Brazier F, Yzet C, Lamrani A, Peyrin-Biroulet L, Fumery M. Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study. Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101561. doi: 10.1016/j.clinre.2020.10.006. Epub 2020 Nov 16. PMID: 33214090.
Copy Download .nbib Format: NLM
Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study.

Journal of Crohn's & colitis

Fumery M, Peyrin-Biroulet L, Nancey S, Altwegg R, Gilletta C, Veyrard P, Bouguen G, Viennot S, Poullenot F, Filippi J, Buisson A, Bozon A, Brazier F, Pouillon L, Flourie B, Boivineau L, Siproudhis L, Laharie D, Roblin X, Diouf M, Treton X.
PMID: 32898232
J Crohns Colitis. 2020 Sep 08; doi: 10.1093/ecco-jcc/jjaa177. Epub 2020 Sep 08.

INTRODUCTION: The approved maintenance regimens for ustekinumab in Crohn's disease (CD) are 90 mg every 8 or 12 weeks. Some patients will partially respond to ustekinumab or will experience a secondary loss of response. It remains poorly known if...

Cite
Fumery M, Peyrin-Biroulet L, Nancey S, et al. Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study. J Crohns Colitis. 2020;doi: 10.1093/ecco-jcc/jjaa177.
Fumery, M., Peyrin-Biroulet, L., Nancey, S., Altwegg, R., Gilletta, C., Veyrard, P., Bouguen, G., Viennot, S., Poullenot, F., Filippi, J., Buisson, A., Bozon, A., Brazier, F., Pouillon, L., Flourie, B., Boivineau, L., Siproudhis, L., Laharie, D., Roblin, X., Diouf, M., & Treton, X. (2020). Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study. Journal of Crohn's & colitis, . https://doi.org/10.1093/ecco-jcc/jjaa177
Fumery, Mathurin, et al. "Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study." Journal of Crohn's & colitis vol. (2020). doi: https://doi.org/10.1093/ecco-jcc/jjaa177
Fumery M, Peyrin-Biroulet L, Nancey S, Altwegg R, Gilletta C, Veyrard P, Bouguen G, Viennot S, Poullenot F, Filippi J, Buisson A, Bozon A, Brazier F, Pouillon L, Flourie B, Boivineau L, Siproudhis L, Laharie D, Roblin X, Diouf M, Treton X. Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study. J Crohns Colitis. 2020 Sep 08; doi: 10.1093/ecco-jcc/jjaa177. Epub 2020 Sep 08. PMID: 32898232.
Copy Download .nbib Format: NLM
Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy.

Journal of immunotherapy (Hagerstown, Md. : 1997)

Montes G, Duval F, Eldani C, Amico S, Gérard E, Dutriaux C, Herran C, Poullenot F, Sole G, Carla L, Guerin C, Célerier P, Prey S.
PMID: 34166302
J Immunother. 2021 Nov-Dec 01;44(9):348-350. doi: 10.1097/CJI.0000000000000381.

Immunotherapy with immune checkpoint inhibitors (ICIs) has improved the prognosis of many cancers; a combination of nivolumab (anti-programmed cell death protein 1) and ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4) is approved as first-line therapy for advanced melanoma, with objective responses...

Cite
Montes G, Duval F, Eldani C, et al. Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy. J Immunother. 2021;44(9):348-350doi: 10.1097/CJI.0000000000000381.
Montes, G., Duval, F., Eldani, C., Amico, S., Gérard, E., Dutriaux, C., Herran, C., Poullenot, F., Sole, G., Carla, L., Guerin, C., Célerier, P., & Prey, S. (2021). Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy. Journal of immunotherapy (Hagerstown, Md. : 1997), 44(9), 348-350. https://doi.org/10.1097/CJI.0000000000000381
Montes, Gaëlle, et al. "Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy." Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 44,9 (2021): 348-350. doi: https://doi.org/10.1097/CJI.0000000000000381
Montes G, Duval F, Eldani C, Amico S, Gérard E, Dutriaux C, Herran C, Poullenot F, Sole G, Carla L, Guerin C, Célerier P, Prey S. Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy. J Immunother. 2021 Nov-Dec 01;44(9):348-350. doi: 10.1097/CJI.0000000000000381. PMID: 34166302.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries